高密度胆固醇功能和斯芬戈-1-酸盐在血管性心痛中的作用
Kei Sasaki1, Hirotaka Ezaki2, Yasuhiro Endo3
1Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan.
概括
这项研究表明,降低胆固醇吸收能力 (CUC) 表明在血管缩性心痛 (VSA) 中功能障碍的高密度脂蛋白 (HDL). 升高的斯芬戈-1-酸盐 (S1P) 水平也与VSA有关,这表明潜在的生物标志物.
科学领域:
- 心血管医学 心血管医学
- 生物化学 生物化学
- 脂质代谢 脂质代谢是什么
背景情况:
- 高密度脂蛋白胆固醇 (HDL-C) 在血管性心痛 (VSA) 中经常降低,但HDL功能的作用尚不清楚.
- 胆固醇吸收能力 (CUC) 通过胆固醇流动来衡量HDL的功能.
- 斯芬戈辛-1-酸盐 (S1P) 是一种与高密度脂质相关的脂质,具有可能与VSA相关的血管保护性.
研究的目的:
- 在患有VSA的患者中评估胆固醇吸收能力 (CUC).
- 在VSA患者中评估血清中斯芬戈-1-酸盐 (S1P) 的水平.
- 探索HDL功能,S1P和VSA病原体之间的关系.
主要方法:
- 包括七十七名患者:32名VSA,21名非VSA (接受乙胆刺激测试) 和24名VSA门诊患者.
- 胆固醇吸收能力 (CUC) 用无细胞测定法测量.
- 量化了血清S1P水平,并分析了与VSA的关联.
主要成果:
- 与非VSA患者相比,VSA患者的CUC较低.
- 在VSA患者中,血清S1P水平显著升高 (1.74 ± 0.76 μM vs 1.31 ± 0.49 μM).
- 升高的S1P水平与VSA显著相关 (OR = 3.14,p = 0.01),即使在调整后.
结论:
- 降低CUC是VSA中HDL功能障碍的新型指标.
- 在接受治疗的VSA患者中,S1P是一个有前途的生物标志物.
- 胆固醇外流通道和脂代谢可能有助于VSA病因.
相关概念视频
Vascular Spasm
1.1K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.1K
Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
433
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
433
Antianginal Drugs: Nitrates and β-Blockers
486
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
486
Antihypertensive Drugs: Action of Calcium Channel Blockers
430
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
430
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124


